Reata, a wholly owned subsidiary of Biogen
1 clinical trials · Sponsor
◉ Watch Reata, a wholly owned subsidiary of Biogen
| Record | Firm | Date |
|---|---|---|
| A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (NCT05895552) | Reata, a wholly owned subsidiary of Biogen | 2023-07-28 |
Track Reata, a wholly owned subsidiary of Biogen automatically
Every clearance here is in the API, with alerts when new ones post.